CNXC Stock Forecast & Price Target

Concentrix is viewed positively because its temporary revenue headwinds from hyperscaler client reductions and offshore shifts appear timing-related rather than structural, while both clients continue to grow with the company in other areas. Q3 revenue was $2.45 billion, non-GAAP operating income reached $309 million with a 12.6% margin, and gross margin improved to 34.6%, showing profitability is holding even as automation and transition costs compress near-term sales. The investment case is further supported by record iX Suite traction, reaffirmed $630 million to $650 million adjusted free cash flow, and a path to debt reduction toward about $3.8 billion year-end net debt and below $3.3 billion in FY27, with valuation around 4x EV/EBITDA leaving room for upside.

Concentrix is facing a negative setup because revenue guidance was cut for the second straight quarter, with Q3 constant-currency revenue down 0.5% and Q4 now guided to decline 3% to 5%, implying a slight full-year revenue decline instead of the ~0.75% growth expected in June. The deterioration reflects a sharper-than-expected mix of offshoring, efficiency-driven client spend cuts, and the compressed exit of two hyperscaler relationships, while healthcare fell 14% and tech and consumer electronics declined 6%. With roughly 25% of revenue historically tied to the top five customers, significant delivery exposure abroad, and fiscal 2026 and fiscal 2027 EPS forecasts cut to $11.01 and $11.57, the fundamentals point to persistent execution and concentration risk.